Chlorambucil is indicated in the treatment of Hodgkin's disease, certain forms of non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, and Waldenstrom's macroglobulinaemia.
Posology and method of administration
The relevant literature should be consulted for full details of the treatment schedules used.
Chlorambucil is an active cytotoxic agent for use only under the direction of physicians experienced in the administration of such agents.
Used as a single agent in the palliative treatment of advanced disease a typical dosage is 0.2 mg/kg/day for 4-8 weeks. Chlorambucil is usually included in combination therapy and a number of regimes have been used. Chlorambucil has been used as an alternative to nitrogen mustard with a reduction in toxicity but similar therapeutic results.
Chlorambucil may be used in the management of Hodgkin's disease in children. The dosage regimes are similar to those used in adults.
Used as a single agent the usual dosage is 0.1-0.2 mg/kg/day for 4-8 weeks initially, maintenance therapy is then given either by a reduced daily dosage or intermittent courses of treatment.
Chlorambucil is useful in the management of patients with advanced diffuse lymphocytic lymphoma and those who have relapsed after radiotherapy. There is no significant difference in the overall response rate obtained with chlorambucil as a single agent and combination chemotherapy in patients with advanced non-Hodgkin's lymphocytic lymphoma.
Chlorambucil may be used in the management of non Hodgkin's disease in children. The dosage regimes are similar to those used in adults.
For full data sheet go to:https://www.medicines.org.uk/emc/product/4656/smpc